FINWIRES · TerminalLIVE
FINWIRES

Sherwin-Williams' Growth Timeline Delayed by 'Unsupportive' Housing Market, UBS Says

By

Sherwin-Williams (SHW) remains well-positioned to benefit from a recovery in the US housing market, but "unsupportive" market conditions are delaying that timeline, UBS said in a note emailed Tuesday.

The analysts said they now forecast the company's earnings to grow at roughly a 5% compound annual rate over the next two years and do not expect above-average growth until 2028 or later.

Sherwin-Williams' "stock deserves a premium [versus] coatings peers due to pricing power, but mix shift and higher leverage from potential [mergers and acquisitions] could become an overhang and risks a derating near-term," the analysts added.

The analysts said their adjusted earnings per share estimates are 5% below consensus for 2027 and roughly in line for 2028. Given the muted growth outlook and lack of a clear catalyst, they believe the stock is unlikely to see a meaningful re-rating in the medium term and now view the risk-reward profile as more balanced.

UBS downgraded Sherwin-Williams from buy to neutral and lowered its price target to $330 from $385.

Price: $293.73, Change: $-1.13, Percent Change: -0.38%

Related Articles

Wire

Johnson Controls' New Business Model Showing Encouraging Signs, UBS Securities Says

Johnson Controls International (JCI) is in the early stages of deploying its new business model focused on improving productivity and early indications are highly encouraging, UBS Securities said in a note Monday.The company is on track to increase revenue at a large facility to $1 billion from $250 million over the next two years without higher labor, footprint, or capital requirement, according to the note.The company has also improved on time delivery, reduced client lead times, and decreased floor space and inventory, analysts wrote.The brokerage said it now expects 2026 earnings per share of $4.96, compared with $4.87 previously, and also anticipates sales growth from business system initiatives.UBS Securities boosted its price target on the stock to $180 per share from $170, while reiterating its buy rating.Shares of Johnson Controls were up more than 5% in Tuesday trading.Price: $141.28, Change: $+7.37, Percent Change: +5.50%

$JCI
Wire

Toyota Motor May US Sales at 238,800 Units, Down 0.6% Year Over Year, Bloomberg Says

Toyota Motor May US Sales at 238,800 Units, Down 0.6% Year Over Year, Bloomberg Says

$TM
Wire

Revolution Medicines' Cancer Drug Darax Seen Holding Lead Over Rivals, RBC Says

Revolution Medicines' (RVMD) cancer drug daraxonrasib is likely to keep its lead over emerging competitors, as some investors may be overstating the ability of rival treatments to match its performance, RBC Capital Markets said Tuesday in a report.RBC said its analysis suggests competing drugs are unlikely to show meaningful differences from daraxonrasib, setting a high bar ahead of upcoming data in pancreatic and lung cancer. Additional results in both diseases are expected to "converge on darax's profile," reinforcing its position, the report said.RBC said it would be a buyer of Revolution shares ahead of clinical updates from other companies, arguing that more data should highlight daraxonrasib's advantages and ease concerns about competition.Because daraxonrasib is expected to play a major role in treating pancreatic cancer, a rival drug would need to be clearly better and show a different safety and efficacy profile to take meaningful market share, the report said.RBC raised its price target on Revolution stock to $182 from $165 with a rating of outperform, speculative risk.Price: $155.68, Change: $-8.00, Percent Change: -4.89%

$RVMD